(MENAFN- Straits Research)
Multiple Myeloma Therapeutics Market Size Analysis
The global multiple myeloma therapeutics market size was valued at USD 29.49 billion in 2025 and is projected to grow from USD 31.29 billion in 2026 to USD 50.25 billion by 2034, registering a CAGR of 6.1% during the forecast period from 2026 to 2034. North America dominated the multiple myeloma therapeutics market with a market share of 45.2% in 2025.
Multiple myeloma is a blood malignancy that affects plasma cells in the bone marrow and white blood cells. White blood cells, often known as WBCs, increase erratically within the bone marrow of a patient undergoing multiple myeloma therapies. The therapy for multiple myeloma is a systematic process carried out in stages. In the beginning, induction therapy is carried out, and then stem cell transplantation is immediately carried out. In the second approach, the patient's stem cells are harvested with the assistance of a machine, which is subsequently frozen and stored. After completing this treatment, the cells will be reintroduced into the patient's body.
Multiple Myeloma Therapeutics Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 29.49 Billion
2026 Market Size: USD 31.29 Billion
2034 Projected Market Size: USD 50.25 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 6.1%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 45.2%
Fastest-Growing Region: Asia Pacific
Asia Pacific CAGR (2026–2034): 8.4%
Segment Insights
By Drug Class Outlook
Leading Segment: Anti-CD38 Monoclonal Antibody
Market Share in 2025: 31.8%
By Distribution Channel Outlook
Fastest-Growing Segment: Online Pharmacies
CAGR: 8.9% (2026–2034)
Download a Free Sample To learn more about this report,
Multiple Myeloma Therapeutics Market Trends
Growing Adoption of Bispecific Antibodies and Next-Generation Targeted Immunotherapies
The multiple myeloma therapeutics market is witnessing significant growth as pharmaceutical companies increasingly develop bispecific antibodies, CAR-T cell therapies, antibody-drug conjugates, and other targeted immunotherapies for patients with relapsed or refractory disease. Bispecific antibodies that engage immune cells and specific targets on myeloma cells are expanding treatment possibilities while offering off-the-shelf alternatives to personalized cellular therapies. Growing research into combination regimens and earlier-line use of advanced therapies is further transforming treatment pathways. Pharmaceutical companies are also investigating new targets to address treatment resistance and disease relapse. These developments are expanding precision treatment options and contributing to overall multiple myeloma therapeutics market growth.
In July 2025, Regeneron received U.S. FDA approval for Lynozyfic (linvoseltamab-gcpt), a BCMAxCD3 bispecific antibody for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy. This development expanded targeted immunotherapy options and reflected positive Multiple Myeloma Therapeutics Market analysis.
Multiple Myeloma Therapeutics Market Dynamics
Market Drivers
Rising Disease Burden and Increasing Adoption of Novel Targeted Therapies
The multiple myeloma therapeutics market is witnessing strong growth as increasing diagnosis of multiple myeloma and improving patient survival create sustained demand for effective treatment across multiple lines of therapy. Treatment has evolved beyond conventional chemotherapy toward proteasome inhibitors, immunomodulatory drugs, monoclonal antibodie, CAR-T cell therapies, and bispecific antibodies. Increasing use of combination regimens is helping clinicians achieve deeper and more durable responses, particularly among patients with relapsed or refractory disease. Advances in diagnostic testing and risk stratification are also enabling more personalized treatment decisions. Continued pharmaceutical research into novel targets and treatment combinations is further expanding therapeutic options and supporting market development.
In January 2025, the U.S. FDA approved a new indication for Johnson & Johnson's Darzalex Faspro-based combination regimen for patients with newly diagnosed multiple myeloma who were eligible for autologous stem cell transplantation.
Market Restraints
High Treatment Costs and Complex Administration of Advanced Therapies
The multiple myeloma therapeutics market faces restraints from the substantial costs associated with long-term combination therapy, cellular treatments, hospitalization, monitoring, and management of treatment-related adverse effects. Multiple myeloma generally requires continuous or sequential treatment because patients can experience relapse after initial therapy. CAR-T cell therapies involve individualized manufacturing and specialized treatment centers, while bispecific antibodies can require careful monitoring for cytokine release syndrome and other complications. Access to advanced therapies can therefore vary significantly across healthcare systems and geographic regions. Reimbursement limitations, manufacturing complexity, and requirements for specialized clinical infrastructure can further restrict adoption despite significant improvements in therapeutic effectiveness.
In April 2025, healthcare providers and manufacturers continued expanding specialized infrastructure for CAR-T and bispecific antibody treatments as cost, manufacturing capacity, patient monitoring, and treatment-center availability remained important barriers to broader access.
Market Opportunities
Expansion of CAR-T Cell Therapies and Bispecific Antibodies into Earlier Treatment Lines
The multiple myeloma therapeutics market offers significant opportunities through next-generation immunotherapies targeting BCMA, GPRC5D, and other disease-associated proteins. CAR-T therapies and bispecific antibodies have demonstrated important activity among heavily pretreated patients, encouraging development in earlier treatment settings and combination regimens. Moving these therapies into earlier lines could substantially expand eligible patient populations and improve long-term disease control. Development of off-the-shelf cellular therapies and improved manufacturing processes could further reduce treatment delays. Pharmaceutical companies are also investigating new combinations involving monoclonal antibodies, targeted agents, and immune-based therapies to overcome treatment resistance and provide more personalized therapeutic strategies.
In July 2025, the U.S. FDA approved Johnson & Johnson's Imaavy, a GPRC5D- and CD3-targeting bispecific antibody, for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy.
Market Challenges
Development of Drug Resistance and Management of Disease Relapse
The multiple myeloma therapeutics market faces challenges because the disease remains difficult to cure and can develop resistance after repeated treatment. Multiple myeloma is biologically heterogeneous, and different malignant plasma-cell populations can respond differently to therapy, allowing resistant clones to emerge over time. Patients receiving multiple treatment lines can also experience cumulative toxicities and declining physical condition, complicating subsequent therapeutic decisions. Even advanced immunotherapies may eventually lose effectiveness because of antigen loss, immune escape, or other resistance mechanisms. Researchers must therefore identify new therapeutic targets, biomarkers, and combination strategies capable of producing durable responses while maintaining acceptable safety profiles.
In June 2025, AbbVie announced positive Phase 3 results for venetoclax in combination therapy for patients with relapsed or refractory multiple myeloma carrying the t(11;14) biomarker, highlighting continued development of biomarker-directed strategies to address disease heterogeneity and treatment resistance.
Multiple Myeloma Therapeutics Market Segmental Analysis
By Drug Class
Anti-CD38 Monoclonal Antibody Dominated the Market with 31.8% Share in 2025
The anti-CD38 monoclonal antibody segment accounted for the largest share of the global multiple myeloma therapeutics market at 31.8% in 2025, supported by the increasing use of targeted antibody-based therapies in multiple myeloma treatment regimens. Anti-CD38 monoclonal antibodies target specific proteins expressed on myeloma cells and are used across different treatment settings, including combination therapies. Increasing adoption of targeted treatment approaches, expanding availability of advanced therapeutic regimens, continued clinical development, and growing emphasis on improving treatment outcomes for patients with multiple myeloma continue to reinforce the segment's dominant market position.
Request Customization to receive a tailored report.
By Distribution Channel
Online Pharmacies is Projected to Register the Fastest Growth at a CAGR of 8.9%
The online pharmacies segment is projected to register the fastest growth in the multiple myeloma therapeutics market at a CAGR of 8.9% during the forecast period, supported by increasing adoption of digital pharmaceutical distribution and growing preference for convenient access to medications. Online pharmacy platforms can facilitate medicine ordering, prescription management, home delivery, and access to pharmaceutical products for patients requiring continued treatment. Expanding digital healthcare infrastructure, increasing adoption of e-pharmacy platforms, greater availability of home delivery services, and growing demand for convenient medication access continue to support the expansion of this distribution channel.
Speak to an Analyst to discuss market opportunities.
Multiple Myeloma Therapeutics Market Regional Outlook
North America Multiple Myeloma Therapeutics Market Analysis
North America dominated the multiple myeloma therapeutics market with the largest 45.2% market share in 2025, representing a market value of USD 13.33 billion. The region is projected to grow at a CAGR of 6.5% during the forecast period. Its leadership is supported by advanced healthcare infrastructure, widespread availability of specialized oncology care, extensive pharmaceutical research, and strong adoption of innovative treatment approaches. Multiple myeloma treatment involves combinations of targeted therapies, immunotherapies, proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and other therapeutic approaches. Continued development of personalized treatment strategies and novel drug combinations is expanding therapeutic options. Strong clinical research capabilities and access to advanced cancer treatment strengthen North America's position in the global multiple myeloma therapeutics market.
United States Multiple Myeloma Therapeutics Market Insights
The United States is an important contributor to the multiple myeloma therapeutics market due to its extensive oncology infrastructure, strong pharmaceutical and biotechnology industry, sophisticated clinical research ecosystem, and widespread availability of advanced cancer therapies. Treatment strategies increasingly incorporate targeted medicines, monoclonal antibodies, immunomodulatory agents, proteasome inhibitors, and cellular therapies according to patient characteristics and disease progression. Specialized cancer centers support diagnosis, treatment selection, clinical trials, and management of relapsed or refractory disease. Pharmaceutical companies continue investigating novel mechanisms and combination regimens intended to improve treatment outcomes. Continued oncology research, therapeutic innovation, and development of personalized treatment approaches support growth of the country's multiple myeloma therapeutics market.
Canada Multiple Myeloma Therapeutics Market Insights
Canada contributes to the multiple myeloma therapeutics market through its developed healthcare system, established oncology centers, clinical research capabilities, and increasing availability of advanced hematological cancer treatments. Patients receive therapies involving different drug classes and treatment combinations based on disease characteristics, previous treatment exposure, and clinical requirements. Specialized hematology and oncology services support diagnosis, treatment monitoring, and management of disease progression. Participation in clinical research also provides opportunities to evaluate emerging therapeutic approaches. Increasing integration of precision medicine and advanced diagnostic technologies can further improve treatment selection. Continued development of oncology services and access to innovative medicines supports long-term growth of Canada's multiple myeloma therapeutics market.
Unlock Regional Insights to access country-level data, & regional trends.
Asia Pacific Multiple Myeloma Therapeutics Market Analysis
Asia Pacific is the fastest-growing region in the multiple myeloma therapeutics market and is expected to expand at a CAGR of 8.4% during the forecast period. The region accounted for 18.7% of the global market in 2025, representing a market value of USD 5.51 billion. Growth is supported by expanding healthcare infrastructure, improving access to oncology treatments, increasing availability of advanced therapeutics, and continued development of pharmaceutical and biotechnology capabilities. Expansion of specialized cancer centers is improving access to diagnosis and treatment across major markets. Increasing clinical research activity and introduction of innovative therapies are broadening available treatment options. These developments support strong expansion of the multiple myeloma therapeutics market across Asia Pacific.
Japan Multiple Myeloma Therapeutics Market Insights
Japan is an important contributor to the multiple myeloma therapeutics market through its sophisticated healthcare system, advanced pharmaceutical industry, specialized hematology services, and strong clinical research capabilities. Multiple myeloma treatment increasingly involves combinations of established and newer therapies selected according to patient characteristics and disease progression. Advanced diagnostic capabilities help clinicians assess disease status and monitor therapeutic response throughout treatment. Pharmaceutical research is supporting development and evaluation of novel targeted and immune-based approaches. Specialized medical centers also contribute to treatment of complex and relapsed cases requiring individualized therapeutic strategies. Continued pharmaceutical innovation, clinical research, and availability of advanced oncology care strengthen Japan's contribution to the Asia Pacific multiple myeloma therapeutics market.
China Multiple Myeloma Therapeutics Market Insights
China plays a significant role in the multiple myeloma therapeutics market due to its large healthcare system, expanding oncology infrastructure, growing pharmaceutical and biotechnology industries, and increasing access to specialized cancer treatment. Development of major cancer centers and hematology departments is improving diagnosis and treatment availability across urban healthcare systems. Domestic and international pharmaceutical companies are expanding research into targeted therapies, monoclonal antibodies, immune-based treatments, and combination regimens. Growing clinical trial activity is also supporting evaluation of emerging treatment approaches. Improvements in diagnostic capabilities and treatment accessibility are broadening the eligible patient population. Continued healthcare modernization reinforces China's importance within the Asia Pacific multiple myeloma therapeutics market.
Europe Multiple Myeloma Therapeutics Market Analysis
Europe accounted for 28.1% of the global multiple myeloma therapeutics market in 2025, reaching a market value of USD 8.29 billion. The region is anticipated to grow at a CAGR of 6.2% during the forecast period. Market development is supported by established oncology infrastructure, strong pharmaceutical research, availability of advanced therapies, and extensive hematology expertise. Multiple myeloma treatment increasingly involves combinations of targeted agents, immunotherapies, and other therapeutic classes designed to control disease progression and extend treatment response. Clinical research continues to evaluate new drug combinations and therapeutic mechanisms. Increasing integration of molecular diagnostics and personalized medicine is further supporting treatment optimization, contributing to continued expansion of the multiple myeloma therapeutics market across Europe.
Germany Multiple Myeloma Therapeutics Market Insights
Germany is an important contributor to the multiple myeloma therapeutics market in Europe due to its advanced healthcare system, sophisticated oncology infrastructure, strong pharmaceutical industry, and extensive clinical research capabilities. Specialized hematology centers provide diagnosis, treatment, monitoring, and management of multiple myeloma across different disease stages. Patients can receive treatment combinations involving targeted therapies, immunomodulatory medicines, proteasome inhibitors, monoclonal antibodies, and other therapeutic approaches. Clinical studies are supporting evaluation of novel therapies and treatment sequences for newly diagnosed and previously treated patients. Growing application of precision diagnostics further supports individualized treatment decisions. Continued oncology research and therapeutic innovation strengthen Germany's position within the European multiple myeloma therapeutics market.
United Kingdom Multiple Myeloma Therapeutics Market Insights
The United Kingdom contributes to the multiple myeloma therapeutics market through its extensive healthcare system, specialized cancer centers, established pharmaceutical research ecosystem, and strong hematology expertise. Treatment approaches increasingly combine different therapeutic classes to achieve deeper and more durable disease control while addressing individual patient requirements. Specialized clinical centers support diagnosis, treatment monitoring, management of relapsed disease, and participation in clinical studies evaluating emerging therapies. Research into immune-based approaches and targeted treatments continues to broaden therapeutic possibilities. Integration of advanced diagnostics can also support improved patient stratification and treatment selection. Continued clinical research and oncology innovation support the United Kingdom's contribution to the European multiple myeloma therapeutics market.
Latin America Multiple Myeloma Therapeutics Market Analysis
Latin America represented 4.6% of the global multiple myeloma therapeutics market in 2025, with a market value of USD 1.36 billion. The region is expected to register a CAGR of 6.9% during the forecast period. Growth is supported by expanding oncology infrastructure, improving access to specialized hematology services, increasing availability of innovative medicines, and development of private healthcare networks. Multiple myeloma management requires continued diagnosis, treatment, and monitoring, creating demand for established and newer therapeutic options. Development of specialized cancer facilities is helping broaden treatment availability in major markets. Increasing participation in pharmaceutical research and clinical studies provides additional opportunities, supporting continued development of the multiple myeloma therapeutics market across Latin America.
Brazil Multiple Myeloma Therapeutics Market Insights
Brazil is an important contributor to the multiple myeloma therapeutics market in Latin America due to its large healthcare system, expanding oncology sector, substantial patient population, and growing availability of specialized hematology services. Cancer centers provide diagnosis, treatment, monitoring, and supportive care for patients requiring long-term management of multiple myeloma. Increasing availability of targeted agents, monoclonal antibodies, immunomodulatory medicines, and other advanced treatments is broadening therapeutic options. Private healthcare facilities and specialized oncology networks also contribute to adoption of newer treatment approaches. Continued participation in clinical research can improve access to emerging therapies. Healthcare expansion and oncology development reinforce Brazil's importance within the regional multiple myeloma therapeutics market.
Middle East and Africa Multiple Myeloma Therapeutics Market Analysis
The Middle East and Africa accounted for 3.4% of the global multiple myeloma therapeutics market in 2025, representing a market value of USD 1 billion. The region is projected to expand at a CAGR of 5.8% during the forecast period. Market development is supported by investment in healthcare infrastructure, expansion of specialized oncology services, improving diagnostic capabilities, and increasing availability of advanced cancer treatments. Development of hospitals and cancer centers is improving access to hematology expertise and therapeutic options in major markets. Greater availability of innovative pharmaceutical products is further broadening treatment possibilities. Continued healthcare modernization and development of specialized oncology capabilities support long-term growth of the multiple myeloma therapeutics market across the region.
UAE (United Arab Emirates) Multiple Myeloma Therapeutics Market Insights
The UAE contributes to the multiple myeloma therapeutics market within the Middle East and Africa through its advanced healthcare infrastructure, expanding oncology services, specialized medical facilities, and access to innovative pharmaceutical treatments. Hospitals and cancer centers provide hematology expertise for diagnosis, treatment planning, therapeutic monitoring, and management of complex disease. Availability of advanced diagnostic technologies supports assessment of disease characteristics and treatment response. Continued development of specialized oncology facilities is also improving access to modern therapeutic approaches and multidisciplinary care. Pharmaceutical companies and healthcare providers contribute to increasing availability of innovative cancer medicines. Continued investment in specialized healthcare strengthens the UAE's role in the regional multiple myeloma therapeutics market.
Multiple Myeloma Therapeutics Market Competitive Landscape
The multiple myeloma therapeutics market is highly competitive, with major companies such as Johnson & Johnson, Bristol Myers Squibb, Amgen, Takeda Pharmaceutical, GSK, Sanofi, AbbVie, Roche, Pfizer, AstraZeneca, and Gilead Sciences competing through immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, bispecific antibodies, CAR-T cell therapies, and other targeted treatments. Competitive differentiation increasingly centers on novel mechanisms of action, combination regimens, earlier-line treatment expansion, and improved depth and durability of response. Johnson & Johnson and Bristol Myers Squibb maintain broad multiple myeloma portfolios, while emerging BCMA- and GPRC5D-targeted therapies are intensifying competition across relapsed and refractory disease settings.
List of Key and Emerging Players in Multiple Myeloma Therapeutics Market
Rhizen Pharmaceuticals S.A.
Johnson and Johnson
Terpenoid Therapeutics Inc.
Ablynx NV
Acceleron Pharma Inc.
IGF Oncology LLC.
ImmunGene Inc.
Millennium Pharmaceuticals Inc.
AB Science SA
AbbVie Inc.
Mirna Therapeutics
RedHill Biopharma Ltd.
Teva Pharmaceutical Industries Ltd.
TG Therapeutics Inc.
MimiVax LLC
Key Industry Developments
May 2025: Johnson & Johnson expanded its multiple myeloma therapeutics portfolio by advancing CARVYKTI® (ciltacabtagene autoleucel) and other oncology treatment initiatives. The company focused on improving treatment options for relapsed and refractory multiple myeloma patients through innovative therapies.
June 2025: Bristol Myers Squibb expanded its multiple myeloma treatment portfolio by advancing Abecma® (idecabtagene vicleucel) and next-generation cell therapy research. The developments focused on improving patient outcomes and expanding access to advanced oncology treatments.
July 2025: Takeda expanded its multiple myeloma therapeutics portfolio through continued development of Ninlaro® (ixazomib) and other oncology solutions. The company focused on combination therapies and improving long-term disease management.
September 2025: Amgen expanded its multiple myeloma treatment portfolio by advancing Kyprolis® (carfilzomib) and innovative oncology research programs. The company focused on targeted therapies and improving treatment effectiveness for patients with difficult-to-treat disease.
Report Scope
Comments
No comment